The investigators are performing a trial with goals to demonstrate the feasibility of imaging
multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic
resonance (MR). The investigators suggest that 64Cu-LLP2A will allow for an accurate
molecular imaging of MM lesions, which will have an important impact on early stage disease
detection and in the long term on the initiation and choice of therapy in these patients.